The article examines the objective, findings, and clinical context described in Prula-cel Shows Early Promise in Lupus.
Approach:
Study population: The efficacy dataset included 22 patients: 16 with lupus nephritis and six with extra-renal SLE. All had at least six months of follow-up; 13 had at least 12 months.
Treatment: Prula-cel is an investigational, off-the-shelf allogeneic gamma delta CAR T therapy targeting B cells through an anti-CD20 CAR.
Key Findings:
At 12 months, 54% of evaluable patients achieved DORIS remission; 50% of evaluable lupus nephritis patients achieved complete renal response.
All patients discontinued immunosuppressants, and all but one reduced corticosteroids to 5 mg or less of prednisone equivalent daily.
The company reported that 12-month responses were generally maintained through 12–21 months of follow-up.
Among 24 safety-evaluable patients, 25% had Grade 1 or 2 cytokine release syndrome; none had CRS above Grade 2, neurotoxicity, IEC-HS, graft-versus-host disease, or dose-limiting toxicities.
Infections occurred in 54% of patients, including Grade 3 or higher infections in 8.3%.
All 22 efficacy-evaluable patients had undetectable CD19-positive B cells followed by naïve-dominant B-cell reconstitution.
Interpretation:
Adicet Bio described the B-cell findings as evidence of an “immune reset.” The reported results are from a Phase I dataset.
Limitations:
The efficacy-evaluable population was small (22 patients), and only 13 had at least 12 months of follow-up.
The context provides no comparator group or detailed study methods.
The findings are company-reported; no publication or source URL was provided.
Conclusion:
Adicet plans a single-arm pivotal study in lupus nephritis patients who responded inadequately to at least two immunosuppressants, with start-up activities expected in the fourth quarter of 2026. The company also plans to discuss potentially including patients with SLE without nephritis.
The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.
